Cancer treatment method for magnetic hypothermia cancer treatment

Patent metadata

Field	Value
Publication number	US-12097266-B2
Application number	US-202318512499-A
Country	US
Kind code	B2
Filing date	Nov 17, 2023
Priority date	Jun 18, 2021
Publication date	Sep 24, 2024
Grant date	Sep 24, 2024

Abstract

A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.

First claim

The invention claimed is:

1. A cancer treatment method for treating a subject having a breast cancer, comprising:
administering to the subject a pharmaceutical composition comprising a nanomedicinal composition,
exposing the subject to an alternating magnetic field after the administering, thereby raising the temperature of the nanomedicinal composition in the subject to increase a rate of release of the nanomedicinal composition and/or hyperthermially treat the breast cancer;
wherein the nanomedicinal composition comprises:
a nanocarrier comprising:
mesosilicalite; and
particles of a magnetic ferrite of formula MFe 2 O 4 disposed in the pores of the mesosilicalite, where M is Cu; and
a pharmaceutical agent mixture comprising cisplatin and curcumin disposed in the pores and/or on a surface of the nanocarrier;

wherein the nanocarrier has a BET surface area of 70 m 2 /g and an average pore volume of 0.1 cm 3 /g,
wherein the nanomedicinal composition releases 88% of the cisplatin and 40-50% of the curcumin over 72 hours in a solution with a pH of 5.6.

2. The cancer treatment method of claim 1 , wherein the mesosilicalite is in the form of particles having a mean particle size of 25 to 500 nm.

3. The cancer treatment method of claim 1 , wherein the magnetic ferrite is present in the nanomedicinal composition an amount of 15 to 45 wt % based on a total weight of the nanocarrier.

4. The cancer treatment method of claim 1 , wherein the magnetic ferrite has a mean particle size of 5 to 50 nm.

5. The cancer treatment method of claim 1 , wherein the pharmaceutical agent mixture further comprises at least one selected from the group consisting of carboplatin and oxaliplatin.

6. The cancer treatment method of claim 1 , wherein the pharmaceutical agent mixture further comprises tamoxifen.

7. The cancer treatment method of claim 1 , wherein the nanomedicinal composition further comprises at least one selected from the group consisting of quercetin, rutin, coenzyme Q10, and gallic acid.

8. The cancer treatment method of claim 1 , wherein a weight ratio of the curcumin to the cisplatin is 1:1 to 10:1 in the nonmedicinal composition.

9. The cancer treatment method of claim 1 , wherein the pharmaceutical agent mixture is present in the nanomedicinal composition in an amount of 5 to 50 wt %, based on a total weight of nanomedicinal composition.

Assignees

• Univ Imam Abdulrahman Bin Faisal

Inventors

• Jermy B Rabindran
• Ravinayagam Vijaya
• Almohazey Dana

Classifications

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title

• A61K2121/00

  Preparations for use in therapy · CPC title

• B82Y40/00

  Manufacture or treatment of nanostructures · CPC title

• B82Y30/00

  Nanotechnology for materials or surface science, e.g. nanocomposites · CPC title

• B82Y25/00

  Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance · CPC title